How leveraging a ‘glocal’ approach supported the assessment of the pricing and reimbursement potential of a breakthrough orphan drug in China Read More
How carefully selecting proximity indicators for meaningful analogue analysis helped to redefine the pricing strategy for a larger target population Read More
How a fast, agile, and robust price triangulation across multiple rare blood disorders supported an asset indication prioritization strategy Read More
How re-shaping an assets early value narrative towards the most impactful clinical scenarios streamlined its potential target indications and led to the next wave of funding Read More
How a deep-dive analysis of pricing analogues informed the pricing strategy of a breakthrough advanced medicinal product in prostate cancer Read More
How a deep understanding of the French IO landscape allowed for the development of core pricing scenarios to inform a client’s decision framework Read More
How creating a unified vision and comprehensive framework for Real-World Evidence (RWE) supported seamless execution of RWE projects Read More
How assessing the pricing and reimbursement risks associated with a product withdrawal supported the action steps to take in key Central and Eastern EU markets Read More
How combining qualitative insights with survey outputs enabled deep understanding of payers’ preferences of the value a phase 3b multiple comparator study will bring in drug-resistant epilepsy Read More
How a DELPHI survey informed the key inputs of a health economic model to support the launch of a breakthrough specialty product Read More
How building a step by step market access strategy created a pricing and value roadmap for a specialty product in a highly competitive and genericized market Read More
How developing an early payer value story and value messages supported a differentiated offer within neurology, covering multiple possible scenarios at global and regional levels Read More
How developing a HTA and pricing framework for orphan drugs across EU5 can help optimize portfolio expansion Read More
How primary research of payers’ data needs and decision-making processes guided global market access activities Read More
How focusing on the operational elements of pricing strategy supported in-country teams to strengthen their approach to pricing incremental innovation Read More
How fostering close communications to prioritize key market access activities, ensured the timely delivery of optimized value materials for specialty assets Read More
How a comprehensive review of the payer landscape is being used to support the development of a novel gene therapy Read More